Literature DB >> 2783657

Recombinant human interleukin-2-induced mitogenic proliferation of in vitro unstimulated bovine intestinal lymphocytes.

A M Nagi1, L A Babiuk.   

Abstract

Recombinant human interleukin-2 (rHIL-2) in the absence or presence of additional stimuli, was able to induce and support the proliferation of lymphocytes isolated from the intra-epithelium, lamina propria and Peyer's patches of the small intestine of normal adult cows. Although dose-dependent effects of rHIL-2 were observed with all three cell populations, concentrations as low as 2.5 U/mL were able to induce DNA synthesis as measured by tritiated thymidine incorporation. Furthermore, rHIL-2 as low as 5.0 U/mL was shown to significantly enhance lymphocyte proliferation in response to mitogenic stimulation. These proliferative responses to rHIL-2 were detected within two days of culture and peaked after five days. Although the extent of the blastogenic response was variable in individual animals, the general pattern of time-course and dose-response to rHIL-2 was similar in all animals tested. The response of all three leukocyte populations to rHIL-2 was dependent on the presence of adherent accessory cells and/or 2-mercaptoethanol. Both nylon wool nonadherent (T cells, null cells) and adherent cells (B cells) were shown to be responsive to rHIL-2. These studies demonstrate that bovine lymphocytes isolated from different anatomical locations of the small intestine are capable of proliferation in response to xenogenic IL-2 without in vitro preactivation signals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783657      PMCID: PMC1255516     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  22 in total

Review 1.  Human interleukin 2: molecular biology, physiology and clinical possibilities.

Authors:  R Mertelsmann; K Welte
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

Review 2.  Intestinal immunity and inflammation: recent progress.

Authors:  C O Elson; M F Kagnoff; C Fiocchi; A D Befus; S Targan
Journal:  Gastroenterology       Date:  1986-09       Impact factor: 22.682

Review 3.  Lymphokines. Progress and promise.

Authors:  D W Horohov; J P Siegel
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

4.  rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2.

Authors:  M H Ben Aribia; E Leroy; O Lantz; D Métivier; B Autran; B Charpentier; T Hercend; A Senik
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

5.  Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes.

Authors:  L T Bich-Thuy; H C Lane; A S Fauci
Journal:  Cell Immunol       Date:  1986-04-01       Impact factor: 4.868

6.  Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.

Authors:  J E Talmadge; R H Wiltrout; D F Counts; R B Herberman; T McDonald; J R Ortaldo
Journal:  Cell Immunol       Date:  1986-10-15       Impact factor: 4.868

Review 7.  Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.

Authors:  M Fletcher; A L Goldstein
Journal:  Lymphokine Res       Date:  1987

8.  T cell triggering by lectins. I. Requirements for interleukin 2 production; lectin concentration determines the accessory cell dependency.

Authors:  E E Roosnek; M C Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

9.  Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody.

Authors:  R Palacios
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

10.  Human recombinant interleukin-2 augments in vitro blastogenesis of bovine and porcine lymphocytes.

Authors:  J L Stott; B W Fenwick; B I Osburn
Journal:  Vet Immunol Immunopathol       Date:  1986-09       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.